Lead Pb 212 TCMC-trastuzumab

**Semantic type:** Amino Acid, Peptide, or Protein|Pharmacologic Substance

**Definition:** A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab conjugated with the bifunctional chelating agent TCMC ((1,4,7,10-Tetra-(2-Carbamoyl Methyl)-Cyclododecane), and radiolabeled with the alpha-emitting isotope lead Pb 212, with potential anti-tumor activity. Upon administration, the antibody moiety of lead Pb 212 TCMC-trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2); after internalization, the radioisotope moiety delivers a cytotoxic dose of alpha radiation to the HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed on the cell surface of a variety of cancer cell types.

**Synonyms:** - Lead Pb 212 TCMC-Herceptin - [212]Pb TCMC-Herceptin - [212]Pb TCMC-trastuzumab